ResearcherWashington University in St. LouisActive in the last 2 years
Usman Younis Panni
Matched on ORCID iD 0000-0003-1325-677X; OpenAlex author ID A5074155587. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2023: 2 papers · 2024: 1 paper
Papers 3
- Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-024-16245-1↗
- Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
- Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-21-0946↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- William G. Hawkins · 3 shared papers, 2023–2024 · strength 0.48
- Paper Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinom… DOI 10.1245/s10434-024-16245-1↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Ryan C Fields · 2 shared papers, 2023–2024 · strength 0.34
- Paper Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinom… DOI 10.1245/s10434-024-16245-1↗
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- John M. Baer · 2 shared papers, 2023 · strength 0.29
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- C. Alston James · 2 shared papers, 2023 · strength 0.29
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- David G DeNardo · 2 shared papers, 2023 · strength 0.29
- Paper Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer. DOI 10.1158/2326-6066.cir-21-0946↗
- Paper Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cance… DOI 10.1007/s00262-023-03463-x↗
- Timothy M. Nywening · 1 shared paper, 2024 · strength 0.19
- Joshua D. Mitchell · 1 shared paper, 2024 · strength 0.19
- Linda R. Peterson · 1 shared paper, 2024 · strength 0.19
- Adetunji T. Toriola · 1 shared paper, 2024 · strength 0.19
- Joseph E. Ippolito · 1 shared paper, 2024 · strength 0.19
- Varintra E. Lander · 1 shared paper, 2023 · strength 0.15
- Graham D. Hogg · 1 shared paper, 2023 · strength 0.15
- Liang‐I Kang · 1 shared paper, 2023 · strength 0.15
- Feng Gao · 1 shared paper, 2023 · strength 0.14
- Daoxiang Zhang · 1 shared paper, 2023 · strength 0.14
- Kian‐Huat Lim · 1 shared paper, 2023 · strength 0.14
- William E. Gillanders · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.